



## Kara Davis

Associate Professor of Pediatrics (Hematology/Oncology)  
Pediatrics - Hematology & Oncology

### CLINICAL OFFICE (PRIMARY)

- **Pediatric Hematology Oncology**

1000 Welch Rd Ste 300

MC 5798

Palo Alto, CA 94304

**Tel** (650) 723-5535      **Fax** (650) 723-5231

### ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Alyssa Ray - Research Administrator

**Email** [alysar@stanford.edu](mailto:alysar@stanford.edu)

### Bio

---

#### BIO

Kara Davis, D.O. is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. Dr. Davis obtained her B.A. from Pennsylvania State University and her D.O. from the Philadelphia College of Osteopathic Medicine. Clinically, she completed her training in Pediatrics at Thomas Jefferson University/A.I. DuPont Children's Hospital and her Heme/Onc fellowship at Lucile Packard Children's Hospital at Stanford. During her fellowship training, Kara worked in the laboratory of Garry Nolan, Ph.D. where she utilized single-cell, high-dimensional analysis platforms to study healthy human B cell development and B cell leukemia. Her research focuses on using single-cell analysis to organize tumor heterogeneity in pediatric cancers, especially blood cancers, as means to determine cell populations associated with clinical risks such as relapse. Clinically, Dr. Davis sees patients with leukemia and is involved with the Cancer Cellular Therapies program with experience in treating children with chimeric antigen receptor (CAR) T-cells and other immunotherapies including checkpoint inhibitors.

#### CLINICAL FOCUS

- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Pediatrics - Hematology & Oncology
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Vice Chair, COG Study ADVL1412, Children's Oncology Group, (2016- present)

#### HONORS AND AWARDS

- Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases, Stanford Maternal and Child Health Research Institute (2018)

- Zelencik Scientist, Harriet and Mary Zelencik Endowed Fund for Faculty Support in Children's Cancer and Blood Diseases (2021)

## **BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS**

- Vice Chair, Biology, ALL Committee, Children's Oncology Group (2024 - present)

## **PROFESSIONAL EDUCATION**

- Medical Education: Philadelphia College of Osteopathic Medicine (2004) PA
- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2010) CA
- Residency: Al Dupont Hospital for Children (2007) DE
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)
- Board Certification: Pediatrics, American Board of Pediatrics (2007)

## **LINKS**

- Lab Website: <https://kldavislab.org>

## **Research & Scholarship**

---

### **CURRENT RESEARCH AND SCHOLARLY INTERESTS**

To address the intrinsic heterogeneity of primary cancers, we have taken a single-cell approach to the study of cancer, particularly childhood leukemia. To organize the tremendous data generated from single-cell studies, we also seek to understand the healthy structure of the tissue of origin.

Using single-cell, high-parameter analysis platforms, especially mass cytometry, to examine primary patient samples, we seek to identify how childhood cancers diverge from their healthy tissue of origin and how cancer cells may exploit developmental states for their benefit. Further, what populations or features of tumor cells are associated with clinical outcomes of interest, such as site of disease, relapse, or drug resistance? Using this knowledge, we can further investigate new approaches to treatment for children with cancer and mechanisms of drug resistance, and with a particular interest in how this relates to immunotherapeutic approaches to cancer treatment.

### **CLINICAL TRIALS**

- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia, Recruiting
- Long Term Follow-Up in Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy, Recruiting
- Outcomes in Pediatric & Young Adult B-Cell Malignancies After Commercially Available Immunotherapy, Recruiting
- Phase I GD2 CAR T Cells for H3K27M-mutant Diffuse Midline Glioma (DMG), Recruiting
- Phase I/Ib Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies, Recruiting
- Phase II Inotuzumab Ozogamicin in Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia(B-ALL), Recruiting
- CTL019 Out of Specification MAP for ALL or DLBCL Patients, Not Recruiting
- Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies, Not Recruiting
- Phase I/II Nivolumab in Recurrent /Refractory Solid Tumors as Single Agent & in Combo w/ Ipilimumab, Not Recruiting
- Phase Ib Autologous CD22 Chimeric Antigen Receptor TCells in Recurrent/Refractory BCell Malignancies, Not Recruiting
- Phase II CTL019 in Pediatric Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia, Not Recruiting
- Phase II CTL019 in Pediatric Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia, Not Recruiting
- Phase II Nilotinib in Pediatric Newly Diagnosis of Ph+ CML, Not Recruiting
- Phase II REinFuse Tisagenlecleucel to Promote Durable B-Cell Aplasia in R/R CD19-Positive B-Cell ALL, Not Recruiting
- Phase II Tisagenlecleucel in First-Line High-Risk B-Cell Acute Lymphoblastic Leukemia + MRD Positive, Not Recruiting

- Phase II Tisagenlecleucel Re-infusion in Peds and AYA w/ ALL Experiencing Loss of B Cell Aplasia, Not Recruiting

## Teaching

---

### STANFORD ADVISEES

#### Postdoctoral Faculty Sponsor

Abhishek Koladiya, Chiara Pirillo, Ao Wang

#### Doctoral Dissertation Reader (NonAC)

Hana Ghanim

## Publications

---

### PUBLICATIONS

- **The tidyomics ecosystem: enhancing omic data analyses.** *Nature methods*  
Hutchison, W. J., Keyes, T. J., Crowell, H. L., Serizay, J., Soneson, C., Davis, E. S., Sato, N., Moses, L., Tarlinton, B., Nahid, A. A., Kosmac, M., Clayssen, Q., Yuan, et al  
2024
- **The tidyomic ecosystem: Enhancing omic data analyses.** *bioRxiv : the preprint server for biology*  
Hutchison, W. J., Keyes, T. J., tidyomics Consortium, Crowell, H. L., Serizay, J., Soneson, C., Davis, E. S., Sato, N., Moses, L., Tarlinton, B., Nahid, A. A., Kosmac, M., Clayssen, Q., et al  
2024
- **Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.** *European journal of haematology*  
Aftandilian, C., Bito, X. R., Berman, D., Zhang, A., Duttagupta, R., Davis, K. L.  
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*  
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al  
2024
- **Inosine induces stemness features in CAR-T cells and enhances potency.** *Cancer cell*  
Klysz, D. D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K. A., Chen, Y., Meier, S., Daniel, B., Sandor, K., Xu, P., Huang, J., Labanieh, L., Keerthi, et al  
2024
- **Stem cell transplantation for ALL: you've always got a donor, why not always use it?** *Hematology. American Society of Hematology. Education Program*  
Shyr, D., Davis, K. L., Bertaina, A.  
2023; 2023 (1): 84-90
- **Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion.** *The Journal of clinical investigation*  
Pan, F., Sarno, J., Jeong, J., Yang, X., Jager, A., Gruber, T. A., Davis, K. L., Cleary, M. L.  
2023
- **Prior Knowledge Integration Improves Relapse Prediction and Identifies Relapse Associated Mechanisms in Childhood B Cell Acute Lymphoblastic Leukemia**  
Koladiya, A., Jager, A., Culos, A., Merchant, M., Liu, Y., Stuani, L., Sarno, J., Domizi, P., Mullighan, C. G., Aghaeepour, N., Bendall, S., Davis, K. L.  
AMER SOC HEMATOLOGY.2023
- **Enrichment in Metabolic Pathway Activation Corresponds to Immunoglobulin Gene Diversity across B Cell Developmental Stages in B-Lymphoblastic Leukemia**  
Simpson, C., Liu, Y., Stuani, L., Jager, A., Baker, C., Adlowitz, D. G., Rock, P. J., Burack, R., Davis, K. L.

AMER SOC HEMATOLOGY.2023

- **Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS**  
Silbert, S. K., Harrison, C., Biery, N., Semchenkova, A., Zerkalenkova, E., Alonso-Saladrigues, A., Utley, K., Aldoss, I., Zhao, L., Fernandes, S., Rubinstein, J. D., Carapia, N., Chang, et al  
AMER SOC HEMATOLOGY.2023
- **CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN- Cytokine Signature**  
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y., Kramer, A., Reschke, A., Jeyakumar, N., Bharadwaj, S., Schultz, L., Ramakrishna, S., Davis, K. L., Sahaf, B., Feldman, et al  
AMER SOC HEMATOLOGY.2023
- **Uridine Synthesis Is the Metabolic Vulnerability in Relapse-Associated B-ALL Cells with Active Pre-BCR Signaling**  
Liu, Y., Jiang, H., Stuani, L., Sarno, J., Domizi, P., Merchant, M., Jedoui, D., Jager, A., Huang, M., Lacayo, N. J., Sakamoto, K. M., Ye, J., Davis, et al  
AMER SOC HEMATOLOGY.2023
- **INSPIRED Symposium Part 4B: CAR T cell correlative studies-established findings and future priorities. *Transplantation and cellular therapy***  
Ligon, J. A., Ramakrishna, S., Ceppi, F., Calkoen, F. G., Diorio, C., Davis, K. L., Jacoby, E., Gottschalk, S., Schultz, L. M., Capitini, C. M.  
2023
- **CNS Repopulation by Hematopoietic-Derived Microglia-Like Cells Corrects Progranulin deficiency. *Research square***  
Colella, P., Sayana, R., Suarez-Nieto, M. V., Sarno, J., Nyame, K., Xiong, J., Vera, L. N., Basurto, J. A., Corbo, M., Limaye, A., Davis, K. L., Abu-Remaileh, M., Gomez-Ospina, et al  
2023
- **Advances in Clinical Mass Cytometry. *Clinics in laboratory medicine***  
Koladiya, A., Davis, K. L.  
2023; 43 (3): 507-519
- **TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS**  
Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B., Davidson, T., Prolo, L., Batchelor, T., Campen, C., Davis, K., Gust, J., Lim, M., Majzner, et al  
OXFORD UNIV PRESS INC.2023
- **Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia. *Nature communications***  
Sarno, J., Domizi, P., Liu, Y., Merchant, M., Pedersen, C. B., Jedoui, D., Jager, A., Nolan, G. P., Gaipa, G., Bendall, S. C., Bava, F., Davis, K. L.  
2023; 14 (1): 2935
- **Inosine Induces Stemness Features in CAR T cells and Enhances Potency. *bioRxiv : the preprint server for biology***  
Klysz, D. D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K. A., Meier, S., Daniel, B., Sandor, K., Xu, P., Huang, J., Labanieh, L., Leruste, A., Bashti, et al  
2023
- **Tumor inflammation-associated neurotoxicity. *Nature medicine***  
Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., Gust, J., Lim, M., Majzner, et al  
2023
- **Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD. *Journal for immunotherapy of cancer***  
Schultz, L., Davis, K. L., Walkush, A., Baggott, C., Erickson, C., Ramakrishna, S., Aftandilian, C., Lacayo, N., Nadel, H. R., Oak, J., Mackall, C. L.  
2023; 11 (2)
- **Single-cell technologies uncover intra-tumor heterogeneity in childhood cancers. *Seminars in immunopathology***  
Lo, Y., Liu, Y., Kammersgaard, M., Koladiya, A., Keyes, T. J., Davis, K. L.  
2023
- **tidytof: a user-friendly framework for scalable and reproducible high-dimensional cytometry data analysis. *Bioinformatics advances***  
Keyes, T. J., Koladiya, A., Lo, Y., Nolan, G. P., Davis, K. L.

2023; 3 (1): vbad071

- **SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.** *Journal for immunotherapy of cancer*  
McNerney, K. O., Richards, R. M., Aguayo-Hiraldo, P., Calkoen, F. G., Talano, J., Moskop, A., Balduzzi, A., Krajewski, J., Dave, H., Vatsayan, A., Callahan, C., Liu, H., Li, et al  
2023; 11 (1)
- **SINGLE CELL METABOLIC CHARACTERIZATION AND TARGETING OF PAX5 REARRANGEMENTS IN A PRECLINICAL MODEL OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA**  
Quadri, M., Sarno, J., Cazzaniga, G., Davis, K., Fazio, G.  
ELSEVIER SCIENCE INC.2023: S128
- **Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients.** *Frontiers in oncology*  
Reschke, A., Richards, R. M., Smith, S. M., Long, A. H., Marks, L. J., Schultz, L., Kamens, J. L., Aftandilian, C., Davis, K. L., Gruber, T., Sakamoto, K. M.  
2022; 12: 1033993
- **Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., De Moerloose, B., Qayed, M., Buechner, J., Pulsipher, M. A., Myers, et al  
2022: JCO2200642
- **Improved Relapse Prediction in Pediatric Acute Myeloid Leukemia By Deconvolving Lineage-Specific and CancerSpecific Features in Single-Cell Data**  
Keyes, T., Jager, A., Krueger, M., Plevritis, S., Tibshirani, R., Aplenc, R., Nolan, G. P., Redell, M. S., Davis, K. L.  
AMER SOC HEMATOLOGY.2022: 6288-6289
- **Proof of Principle for Intracarotid Injection of Leukemia As Model for Late Stage Central Nervous System Leukemia**  
Wang, C., Rodrigues, A., Chernikova, S., Davis, K. L., Gephart, M.  
AMER SOC HEMATOLOGY.2022: 11522-11523
- **Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation**  
Schultz, L. M., Ramakrishna, S., Baskar, R., Richards, R. M., Moon, J., Baggott, C., Fujimoto, M., Kunicki, M., Li, A., Jariwala, S., Erickson, C., Jacobs, A., Yamabe, et al  
AMER SOC HEMATOLOGY.2022: 10300-10302
- **Plasma Microbial Cell-Free DNA to Characterize Infection Vs Cytokine Release Syndrome in Pediatric Patients with B ALL after CAR T Cell Therapy**  
Aftandilian, C., Bito, X., Berman, D. M., Duttgupta, R., Davis, K. L.  
AMER SOC HEMATOLOGY.2022: 4681-4683
- **Single-Cell Proteomic Analysis Defines Metabolic Heterogeneity in Response to Venetoclax in AML**  
Stuani, L., Jager, A., Sahal, A., Koladiya, A., Sarno, J., Domizi, P., Liu, Y., De Mas, V., Recher, C., Vergez, F., Sarry, J., Davis, K. L.  
AMER SOC HEMATOLOGY.2022: 1028-1029
- **CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study**  
Jeyakumar, N., Ramakrishna, S., Frank, M. J., Sahaf, B., Feldman, S. A., Miklos, D. B., Mackall, C. L., Davis, K. L., Muffly, L., Schultz, L. M.  
AMER SOC HEMATOLOGY.2022: 2374-2375
- **IKAROS MEDIATES ANTIGEN ESCAPE FOLLOWING CD19 CAR T CELL THERAPY IN R/R B-ALL**  
Domizi, P., Sarno, J., Jager, A., Rotiroti, M., Baskar, R., Reynolds, W., Sahaf, B., Bendall, S., Mullighan, C., Leahy, A., Myers, R., Grupp, S., Majzner, et al  
WILEY.2022
- **SARS-COV-2 INFECTIONS IN PEDIATRIC AND YOUNG ADULT (YA) RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: AN INTERNATIONAL REGISTRY REPORT**  
Mcnerney, K., Richards, R., Aguayo-Hiraldo, P., Calkoen, F., Talano, J., Moskop, A., Balduzzi, A., Krajewski, J., Dave, H., Callahan, C., Li, Y., Davis, K., Maude, et al

WILEY.2022: S327

- **A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., Mackall, C. L.  
2022
- **Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells**  
Majzner, R. G., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Barsan, V., Richards, R., Campen, C., Reschke, A., Toland, A., Baggott, et al  
AMER ASSOC CANCER RESEARCH.2022
- **MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS**  
Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Barsan, V., Richards, R., Campen, C., Reschke, A., Toland, et al  
OXFORD UNIV PRESS INC.2022: 20-21
- **Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., Davis, K. L.  
2022; 42: 1-14
- **Cytoflin enables integrated analysis of public mass cytometry datasets using generalized anchors.** *Nature communications*  
Lo, Y., Keyes, T. J., Jager, A., Sarno, J., Domizi, P., Majeti, R., Sakamoto, K. M., Lacayo, N., Mullighan, C. G., Waters, J., Sahaf, B., Bendall, S. C., Davis, et al  
2022; 13 (1): 934
- **GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.** *Nature*  
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, et al  
2022
- **An instructive role for Interleukin-7 receptor alpha in the development of human B-cell precursor leukemia.** *Nature communications*  
Geron, I., Savino, A. M., Fishman, H., Tal, N., Brown, J., Turati, V. A., James, C., Sarno, J., Hameiri-Grossman, M., Lee, Y. N., Rein, A., Maniriho, H., Birger, et al  
1800; 13 (1): 659
- **Understanding the hematopoietic factory during acute lymphoblastic leukemia.** *Pediatric research*  
Davis, K. L.  
1800
- **Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.** *Cancers*  
Youn, M., Smith, S. M., Lee, A. G., Chae, H., Spiteri, E., Erdmann, J., Galperin, I., Jones, L. M., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N., Dahl, et al  
1800; 13 (24)
- **Chromatin Content Capture Reveals Acute Leukaemia Oncogenic Vulnerability Point in Human B Cell Development**  
Baskar, R., Favaro, P., Reynolds, W. D., Domizi, P., Tsai, A. G., Davis, K. L., Bendall, S.  
AMER SOC HEMATOLOGY.2021
- **Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL**  
Domizi, P., Sarno, J., Jager, A., Baskar, R., Reynolds, W. D., Sahaf, B., Bendall, S., Mullighan, C. G., Leahy, A., Myers, R. M., Grupp, S. A., Sotillo, E., Barrett, et al  
AMER SOC HEMATOLOGY.2021
- **Inhibition of Pre-BCR Signaling Mediates a Metabolic Switch in B-Cell Progenitor Acute Lymphoblastic Leukemia**  
Liu, Y., Stuani, L., Jedoui, D., Merchant, M., Jager, A., Sarno, J., Mullighan, C. G., Hartmann, F. J., Bendall, S., Davis, K. L.  
AMER SOC HEMATOLOGY.2021

- **Glucocorticoid-Resistant B-Cell Acute Lymphoblastic Leukemic Cells Can be Targeted By BCR-Signaling Inhibition**  
Sarno, J., Domizi, P., Liu, Y., Merchant, M., Jedoui, D., Jager, A., Biondi, A., Gaipa, G., Bava, A., Davis, K. L.  
AMER SOC HEMATOLOGY.2021
- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**  
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al  
AMER SOC HEMATOLOGY.2021
- **Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study**  
Boyer, M. W., Chaudhury, S., Davis, K. L., Driscoll, T., Grupp, S. A., Hermiston, M., John, S., Keating, A. K., Kovacs, C., Myers, G., Phillips, C. L., Pulsipher, M. A., Talano, et al  
CIG MEDIA GROUP, LP.2021: S262-S263
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*  
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al  
2021
- **GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.**  
Majzner, R. G., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggott, et al  
AMER ASSOC CANCER RESEARCH.2021
- **SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY**  
Mochizuki, A., Ramakrishna, S., Good, Z., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggot, et al  
OXFORD UNIV PRESS INC.2021: 39
- **GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG**  
Majzner, R., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Martin, A., Toland, et al  
OXFORD UNIV PRESS INC.2021: 49-50
- **Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.** *The Laryngoscope*  
Sidell, D. R., Balakrishnan, K., Best, S. R., Zur, K., Buckingham, J., De Alarcon, A., Baroody, F. M., Bock, J. M., Boss, E. F., Bower, C. M., Campisi, P., Chen, S. F., Clarke, et al  
2021
- **Mass Cytometry of Hematopoietic Cells.** *Methods in molecular biology (Clifton, N.J.)*  
Jager, A., Sarno, J., Davis, K. L.  
2021; 2185: 65–76
- **Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer.** *JCO clinical cancer informatics*  
Kerlavage, A. R., Kirchoff, A. C., Guidry Auvil, J. M., Sharpless, N. E., Davis, K. L., Reilly, K., Reaman, G., Penberthy, L., Deapen, D., Hwang, A., Durbin, E. B., Gallotto, S. L., Aplenc, et al  
2021; 5: 881-896
- **Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia.** *Pediatric blood & cancer*  
Marquez, C. P., Montiel-Esparza, R., Hui, C., Schultz, L. M., Davis, K. L., Hoppe, R. T., Donaldson, S. S., Ramakrishna, S., Hiniker, S. M.  
2020: e28870
- **Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement** *JACC: CARDIOONCOLOGY*  
Han, B., Montiel-Esparza, R., Chubb, H., Kache, S., Schultz, L. M., Davis, K. L., Ramakrishna, S., Su, L.

2020; 2 (4): 666–70

- **Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement.** *JACC. CardioOncology*  
Han, B., Montiel-Esparza, R., Chubb, H., Kache, S., Schultz, L. M., Davis, K. L., Ramakrishna, S., Su, L.  
2020; 2 (4): 666-670
- **Multiplexed ion beam imaging to describe tumor-immune microenvironment and tumor heterogeneity in neuroblastoma.**  
Kammersgaard, M. B., Bosse, M., Martinez, D., Bosse, K. R., Maris, J. M., Mackall, C. L., Angelo, R. M., Davis, K. L.  
AMER ASSOC CANCER RESEARCH.2020
- **Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions** *NATURE MACHINE INTELLIGENCE*  
Culos, A., Tsai, A. S., Stanley, N., Becker, M., Ghaemi, M. S., Mcllwain, D. R., Fallahzadeh, R., Tanada, A., Nassar, H., Espinosa, C., Xenochristou, M., Ganio, E., Peterson, et al  
2020
- **Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions.** *Nature machine intelligence*  
Culos, A., Tsai, A. S., Stanley, N., Becker, M., Ghaemi, M. S., Mcllwain, D. R., Fallahzadeh, R., Tanada, A., Nassar, H., Espinosa, C., Xenochristou, M., Ganio, E., Peterson, et al  
2020; 2 (10): 619-628
- **Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.** *Journal for immunotherapy of cancer*  
Schultz, L., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J., Bertaina, A., Mackall, C., Feldman, et al  
2020; 8 (2)
- **Progressive B Cell Loss in Revertant X-SCID.** *Journal of clinical immunology*  
Lin, C. H., Kuehn, H. S., Thauland, T. J., Lee, C. M., De Ravin, S. S., Malech, H. L., Keyes, T. J., Jager, A., Davis, K. L., Garcia-Lloret, M. I., Rosenzweig, S. D., Butte, M. J.  
2020
- **Validation of a model of pediatric leukemia based on pluripotent stem cells using mass cytometry**  
Domingo-Reines, J., Kimmey, S., Vijayaragavan, K., Bosse, M., Bendall, S., Davis, K., Ramos-Mejia, V.  
AMER ASSOC CANCER RESEARCH.2020: 95
- **Using single-cell, high-dimensional approaches to unravel tumor heterogeneity in pediatric cancer**  
Davis, K. L.  
AMER ASSOC CANCER RESEARCH.2020: 29–30
- **A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry.** *Cytometry. Part A : the journal of the International Society for Analytical Cytology*  
Keyes, T. J., Domizi, P., Lo, Y., Nolan, G. P., Davis, K. L.  
2020
- **Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.** *Current oncology reports*  
Barsan, V., Ramakrishna, S., Davis, K. L.  
2020; 22 (2): 11
- **Supercharging your CAR.** *Blood*  
Ramakrishna, S. n., Davis, K. L.  
2020; 135 (9): 593–94
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*  
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al  
2020
- **Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.** *The Lancet. Oncology*  
Davis, K. L., Fox, E. n., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X. n., Minard, C. G., Voss, S. n., Berg, S. L., Weigel, B. J., Mackall, C. L.

2020

- **RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.** *Oncotarget*  
Chae, H. D., Dutta, R. n., Tiu, B. n., Hoff, F. W., Accordi, B. n., Serafin, V. n., Youn, M. n., Huang, M. n., Sumarsono, N. n., Davis, K. L., Lacayo, N. J., Pigazzi, M. n., Horton, et al  
2020; 11 (25): 2387–2403
- **Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.** *The Lancet. Oncology*  
Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H., Buechner, J., De Moerloose, B., Davis, K. L., Nemecek, E., Driscoll, T., Mechinaud, F., Boissel, et al  
2019
- **Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia** *CANCER RESEARCH*  
Diaz-Flores, E., Comeaux, E. Q., Kim, K. L., Melnik, E., Beckman, K., Davis, K. L., Wu, K., Akutagawa, J., Bridges, O., Marino, R., Wohlfeil, M., Braun, B. S., Mullighan, et al  
2019; 79 (9): 2339–51
- **BCL-2 is a Therapeutic Target For Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.** *Cancer research*  
Diaz-Flores, E., Comeaux, E. Q., Kim, K. L., Melnik, E. M., Beckman, K., Davis, K. L., Wu, K., Akutagawa, J., Bridges, O., Marino, R., Wohlfeil, M., Braun, B. S., Mullighan, et al  
2019
- **A novel platform for isotype-specific testing of autoantibodies.** *PLoS one*  
Carter, K. L., Treurnicht, A., Davis, K. L., Kumar, R. B., Feldman, B. J.  
2019; 14 (2): e0211596
- **High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.** *Blood advances*  
Jeong, J. n., Jager, A. n., Domizi, P. n., Pavel-Dinu, M. n., Gojenola, L. n., Iwasaki, M. n., Wei, M. C., Pan, F. n., Zehnder, J. L., Porteus, M. H., Davis, K. L., Cleary, M. L.  
2019; 3 (19): 2825–35
- **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**  
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al  
AMER SOC HEMATOLOGY.2018
- **Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia**  
Grupp, S. A., Maude, S. L., Rives, S., Baruchel, A., Boyer, M. W., Bittencourt, H., Bader, P., Buchner, J., Laetsch, T. W., Stefanski, H., Myers, G., Qayed, M., Pulsipher, et al  
AMER SOC HEMATOLOGY.2018
- **1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)**  
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A., Mavroukakis, S., Sahaf, B., Kong, K. A., Muffly, L. S., Kim, S., Meyer, E. H., Fry, T. J., Qin, et al  
AMER SOC HEMATOLOGY.2018
- **Glucocorticoids-Resistant Leukemic B-Cells Undergo a Phenotypic Change That Increases Sensitivity to SRC/ABL Inhibition**  
Sarno, J., Pedersen, C., Jager, A., Burns, T., Gaipa, G., Nolan, G. P., Bava, A., Davis, K. L.  
AMER SOC HEMATOLOGY.2018
- **Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML**  
Aftandilian, C., Sakamoto, K. M., Davis, K. L., Dahl, G., Lacayo, N. J.  
AMER SOC HEMATOLOGY.2018
- **Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q., Davis, K. L., Owens, D. K., Goldhaber-Fiebert, J. D.  
2018: JCO2018790642

- **Individualized drug combination based on single-cell drug perturbations**  
Anchang, B., Davis, K., Fienberg, H., Bendall, S., Karacosta, L., Nolan, G., Plevritis, S. K.  
AMER ASSOC CANCER RESEARCH.2018
- **False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy** *BLOOD*  
Laetsch, T. W., Maude, S. L., Milone, M. C., Davis, K. L., Krueger, J., Cardenas, A., Eldjerou, L. K., Keir, C. H., Wood, P. A., Grupp, S. A.  
2018; 131 (23): 2596–98
- **SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.** *Oncotarget*  
Sarno, J., Savino, A. M., Buracchi, C., Palmi, C., Pinto, S., Bugarin, C., Jager, A., Bresolin, S., Barber, R. C., Silvestri, D., Israeli, S., Dyer, M. J., Cazzaniga, et al  
2018; 9 (33): 22872–85
- **Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.** *Nature medicine*  
Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaepour, N., Simonds, E. F., White, L., Lacayo, N. J., Fantl, W. J., Fazio, G., Gaipa, G., Biondi, A., Tibshirani, et al  
2018; 24 (4): 474–83
- **Publisher Correction: High-resolution myogenic lineage mapping by single-cell mass cytometry.** *Nature cell biology*  
Porpiglia, E., Samusik, N., Van Ho, A. T., Cosgrove, B. D., Mai, T., Davis, K. L., Jager, A., Nolan, G. P., Bendall, S. C., Fantl, W. J., Blau, H. M.  
2018
- **Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*  
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, et al  
2018; 378 (5): 439–48
- **Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways** *ONCOTARGET*  
Chae, H., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., Sakamoto, K. M.  
2018; 9 (4): 4301–17
- **DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.** *Proceedings of the National Academy of Sciences of the United States of America*  
Anchang, B. n., Davis, K. L., Fienberg, H. G., Williamson, B. D., Bendall, S. C., Karacosta, L. G., Tibshirani, R. n., Nolan, G. P., Plevritis, S. K.  
2018; 115 (18): E4294–E4303
- **Single-cell mass cytometry and machine learning predict relapse in childhood leukemia.** *Molecular & cellular oncology*  
Sarno, J., Davis, K. L.  
2018; 5 (5): e1472057
- **Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia** *Journal of Clinical Oncology*  
Lin, J., Lerman, B. J., Barnes, J., Boursiquot, B., Tan, Y., Robinson, A., Davis, K., Owens, D., Goldhaber-Fiebert, J.  
2018
- **Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry** *JOURNAL OF IMMUNOLOGY*  
Kunicki, M. A., Hernandez, L., Davis, K. L., Bacchetta, R., Roncarolo, M.  
2018; 200 (1): 336–46
- **High-resolution myogenic lineage mapping by single-cell mass cytometry** *NATURE CELL BIOLOGY*  
Porpiglia, E., Samusik, N., Van Ho, A. T., Cosgrove, B. D., Mai, T., Davis, K. L., Jager, A., Nolan, G. P., Bendall, S. C., Fantl, W. J., Blau, H. M.  
2017; 19 (5): 558-?
- **New developments in immunotherapy for pediatric solid tumors.** *Current opinion in pediatrics*  
Schultz, L. M., Majzner, R. n., Davis, K. L., Mackall, C. n.  
2017
- **Checkpoint inhibition in pediatric hematologic malignancies** *PEDIATRIC HEMATOLOGY AND ONCOLOGY*  
Davis, K. L., Agarwal, A. M., Verma, A. R.

2017; 34 (6-7): 379–94

- **Immunotherapy for acute lymphoblastic leukemia: from famine to feast** *BLOOD ADVANCES*  
Davis, K. L., Mackall, C. L.  
2016; 1 (3): 265–69
- **Automated mapping of phenotype space with single-cell data** *NATURE METHODS*  
Samusik, N., Good, Z., Spitzer, M. H., Davis, K. L., Nolan, G. P.  
2016; 13 (6): 493–?
- **Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis** *CELL*  
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., Finck, R., Gedman, A. L., Radtke, et al  
2015; 162 (1): 184–197
- **The Split Virus Influenza Vaccine rapidly activates immune cells through Fc gamma receptors** *VACCINE*  
O’Gorman, W. E., Huang, H., Wei, Y., Davis, K. L., Leipold, M. D., Bendall, S. C., Kidd, B. A., Dekker, C. L., Maecker, H. T., Chien, Y., Davis, M. M.  
2014; 32 (45): 5989–5997
- **The Split Virus Influenza Vaccine rapidly activates immune cells through Fc $\gamma$  receptors.** *Vaccine*  
O’Gorman, W. E., Huang, H., Wei, Y., Davis, K. L., Leipold, M. D., Bendall, S. C., Kidd, B. A., Dekker, C. L., Maecker, H. T., Chien, Y., Davis, M. M.  
2014; 32 (45): 5989–5997
- **Single-Cell Trajectory Detection Uncovers Progression and Regulatory Coordination in Human B Cell Development** *CELL*  
Bendall, S. C., Davis, K. L., Amir, E. D., Tadmor, M. D., Simonds, E. F., Chen, T. J., Shenfeld, D. K., Nolan, G. P., Pe’er, D.  
2014; 157 (3): 714–725
- **viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.** *Nature biotechnology*  
Amir, E. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., Pe’er, D.  
2013; 31 (6): 545–552
- **Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria: A Single-Center Experience.** *American journal of clinical pathology*  
Davis, K. L., Marina, N., Arber, D. A., Ma, L., Cherry, A., Dahl, G. V., Heerema-McKenney, A.  
2013; 139 (6): 818–825
- **Ikaros: master of hematopoiesis, agent of leukemia.** *Therapeutic advances in hematology*  
Davis, K. L.  
2011; 2 (6): 359–368
- **Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia** *PEDIATRIC BLOOD & CANCER*  
Simonds, E. F., Davis, K. L., Lacayo, N. J.  
2009; 53 (4): 525–526
- **Why Are Young Infants Tested for Herpes Simplex Virus?** *PEDIATRIC EMERGENCY CARE*  
Davis, K. L., Shah, S. S., Frank, G., Eppes, S. C.  
2008; 24 (10): 673–678